| 1 |
2023.03.01_Draft_ GSR 157(E)_Medical Device Rule 18 and 19 Amendment (Central Government and State Government) |
2023-Mar-01 |
|
642 KB |
| 2 |
2023.03.01_Draft_GSR 158(E)_Notification of Gangavaram port |
2023-Mar-01 |
|
569 KB |
| 3 |
DR_G.S.R. 227(E) dt_29.03.2022_To include colour of disinfectants in rule 127 of Drugs Rules 1945 |
2022-Mar-29 |
|
1527 KB |
| 4 |
DR_G.S.R. 75(E) dt_01.02.2022_Inclusion of Acitretin in Sch H of Drugs Rules 1945 |
2022-Feb-01 |
|
1346 KB |
| 5 |
MDR_G.S.R. 797(E) dt_18.10.2019_Registration of Certain Medical Devices_chapter-IIIA |
2019-Oct-18 |
|
370 KB |
| 6 |
DR_G.S.R. 214(E) dt_11.03.2019_Notification of ICD Dhannad Indore in Madhya Pradesh for import of drugs under Rule 43A |
2019-Mar-11 |
|
316 KB |
| 7 |
DR_G.S.R.187(E) dt_06.03.2019_Amendment in Form 45 and Form 46 under Schedule-A of D&C Rules 1945 |
2019-Mar-06 |
|
323 KB |
| 8 |
MDR_G.S.R.188(E) dt_06.03.2019_Amendment in Form MD-10 to replace the SLA as issuing authority with CLA in MDR 2017 |
2019-Mar-06 |
|
315 KB |
| 9 |
DR_G.S.R.152(E) dt_26.02.2019_Condition of licence for undertaking on brand or trade names of drugs |
2019-Feb-26 |
|
235 KB |
| 10 |
MDR_G.S.R. 87(E) dt_04.02.2019_Exemption of State & Central Govt testing labs from NABL accreditation for two years under MDR 2017 |
2019-Feb-04 |
|
329 KB |
| 11 |
DR_G.S.R. 88(E) dt_04.02.2019_Omission of provision for writing brand name in brackets in Rule 96 of D &C Rules 1945 |
2019-Feb-04 |
|
312 KB |
| 12 |
MDR_G.S.R. 1187(E) dt_07.12.2018_Amendment of Rule 91 and the Second Schedule for fees of free sale certificate in the MDR 2017 |
2018-Dec-07 |
|
340 KB |
| 13 |
DR_G.S.R. 334(E) dt_04.04.2018_Amendment of Rule 122 (E)_inclusion of Stem Cell in New Drug definition |
2018-Apr-04 |
|
1740 KB |
| 14 |
DR_G.S.R. 1368(E) dt_03.11.2017_Amendment in Sch K (serial no 34)_93 percent oxygen |
2017-Nov-03 |
|
1585 KB |
| 15 |
DR_G.S.R. 319(E) dt_31.03.2017_Perpetual Licensing |
2017-Mar-31 |
|
1201 KB |
| 16 |
DR_G.S.R. 302(E) dt_30.03.2017_Font size of proper name |
2017-Mar-30 |
|
1149 KB |
| 17 |
DR_G.S.R. 101(E) dt_02.02.2017_Addition to rule 122P Scg F Sch K |
2017-Feb-02 |
|
1116 KB |
| 18 |
DR_G.S.R. 102(E) dt_02.02.2017_Amendment rule 2, 74, 74B, 76,78_BCS classification_BABE |
2017-Feb-02 |
|
1120 KB |
| 19 |
DR_G.S.R. 80(E) dt_01.02.2017_Amendment rule 67F, 67G, 85E, Sch-K and Sch MI |
2017-Feb-01 |
|
1139 KB |
| 20 |
DR_G.S.R. 357(E) dt_29.03.2016_Sch M III_QMS for notified Medical devices and Invitro Diagnostics |
2016-Mar-29 |
|
485 KB |
| 21 |
DR_G.S.R. 312(E) dt_16.03.2016_Schedule K_Exemptions for Homeopathic hair oils, Custom mededevices, Zinc sulfate tablets |
2016-Mar-16 |
|
145 KB |
| 22 |
DR_G.S.R. 268(E) dt_01.03.2016_Amendment Rule 43A_Addition of ports |
2016-Mar-01 |
|
127 KB |
| 23 |
DR_G.S.R. 69(E) dt_03.02.2015_Amendment rule 122DA, Sch A, Sch Y_Definition of NCE CT GCT |
2015-Feb-03 |
|
160 KB |
| 24 |
DR_G.S.R. 350(E) dt_23.05.2014_Omittion in Sch Q and Inclusion in Sch S |
2014-May-23 |
|
98 KB |
| 25 |
DR_G.S.R. 311(E) dt_05.05.2014_Prohibitions of Import of Cosmetics tested on animals |
2014-May-05 |
|
871 KB |
| 26 |
DR_G.S.R. 311(E) dt_05.05.2014_Insertion of Rule 135B for prohibition of import of cosmetics to be tested on animals |
2014-May-05 |
|
871 KB |
| 27 |
DR_G.S.R. 292(E) dt_24.04.2014_Compensation in case of injury durign Clinical Trial |
2014-Apr-24 |
|
116 KB |
| 28 |
DR_G.S.R. 176(E) dt_11.03.2014_74,74A,74B,78,78A_No advertisement for Sch H, H1 and X drugs |
2014-Mar-11 |
|
96 KB |
| 29 |
DR_G.S.R. 364(E) dt_06.07.2013_Audio Video recording of Informed consen |
2013-Jul-06 |
|
283 KB |
| 30 |
DR_G.S.R. 249(E) dt_22.03.2012_Rule 161_labelling of Ayurvedic or Unani Drugs |
2012-Mar-22 |
|
46 KB |
| 31 |
DR_G.S.R. 228(E) dt_20.03.2012_Incorporation of Sc-H1 |
2012-Mar-20 |
|
124 KB |
| 32 |
DR_G.S.R. 105(E) dt_25.02.2008_Sch M-IV_GMP for Invitro diagnostic reagents or kits |
2008-Feb-25 |
|
1516 KB |
